| Literature DB >> 33986916 |
Qing Xiao1, Lidan Xiong2,3, Jie Tang2,3, Li Li1,2,3, Li Li1,2,3.
Abstract
Together with nitric oxide (NO) and carbon monoxide (CO), hydrogen sulfide (H2S) is now recognized as a vital gaseous transmitter. The ubiquitous distributions of H2S-producing enzymes and potent chemical reactivities of H2S in biological systems make H2S unique in its ability to regulate cellular and organ functions in both health and disease. Acting as an antioxidant, H2S can combat oxidative species such as reactive oxygen species (ROS) and reactive nitrogen species (RNS) and protect the skin from oxidative stress. The aberrant metabolism of H2S is involved in the pathogenesis of several skin diseases, such as vascular disorders, psoriasis, ulcers, pigment disorders, and melanoma. Furthermore, H2S donors and some H2S hybrids have been evaluated in many experimental models of human disease and have shown promising therapeutic results. In this review, we discuss recent advances in understanding H2S and its antioxidant effects on skin pathology, the roles of altered H2S metabolism in skin disorders, and the potential value of H2S as a therapeutic intervention in skin diseases.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33986916 PMCID: PMC8079204 DOI: 10.1155/2021/6652086
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Production of H2S in the skin. CBS catalyses the generation of cystathionine from the substrates homocysteine and serine and liberates H2S from a combination of cysteine and homocysteine. CSE mainly converts cysteine into H2S, pyruvate, and ammonia. 3-MST generates H2S from 3-mercaptopyruvate produced by cysteine aminotransferase. CBS: cystathionine β-synthase; CSE: cystathionine γ-lyase; GSH: glutathione; 3-MST: 3-mercaptopyruvate sulfide transferase; CAT, cysteine aminotransferase.
Figure 2The structure of skin. The uppermost layer is the epidermis, the second layer is the dermis, and the deepest layer is the subcutaneous tissue hypodermis. The area indicated by the rectangle reveals that the epidermis is divided into five layers of cells.
Figure 3The role of H2S in the skin. Blue arrow: induction or stimulation; red arrow: prevention or inhibition. COX: cyclooxygenases; NO: nitric oxide; MAPK: mitogen-activated protein kinase; ERK: extracellular regulated protein kinase; NF-κB: nuclear factor-κB; NET: neutrophil extracellular trap; GSH: glutathione; ONOO−: peroxynitrite; O2−: superoxide anion; H2O2: hydrogen peroxide; ROS: reactive oxygen species; VEGF: vascular endothelial growth factor; EGF: epidermal growth factor; PDGF: platelet-derived growth factor; HIF-1α: hypoxia inducible factor-1α; eNOS: endothelial nitric oxide synthase; mTOR: mammalian target of rapamycin; Akt: protein kinase B; PI3K: phosphatidylinositol 3-kinase.
Figure 4The role of H2S in skin cancers. The diagram shows the potential mechanisms involved in the anticancer effects. Blue arrow: induction or stimulation; red arrow: prevention or inhibition.
Summary of the regulatory effects of different H2S donors on various skin cell types/tissues.
| Cells/tissues | Target | H2S donor(s) | Effects | Ref. |
|---|---|---|---|---|
| Cutaneous vessels | COX and NO vasodilatory signalling pathway | NaHS and Na2S | Vasodilatation | [ |
| HaCaT cells | p38, MAPK, ERK, and NF- | NaHS | Inhibit the TNF- | [ |
| HaCaT cells | ROS-activated NF- | NaHS | Inhibit chemical hypoxia-induced cytotoxicity and inflammation | [ |
| HaCaT cells | Autophagy | NaHS | Promote proliferation and differentiation | [ |
| Endothelial progenitor cell | Angiopoietin-1 | NaHS and 4-hydroxythiobenzamide | Improve diabetic wound healing | [ |
| Mouse skin | NETs and ROS-induced MAPK, ERK1/2, and p38 signaling pathways | Na2S | Improve diabetic wound healing | [ |
| Ischemic mouse adductor muscle | VEGF, EGF, PDGF, HIF-1 | Na2S | Promote ischemic diabetic wound healing | [ |
| Granulation tissues | VEGF | NaHS-containing ointment | Accelerate diabetic wound healing | [ |
| Primary human epidermal melanocytes | Melanogenic enzymes (MITF, TYR, and TRP-1) | NaHS | Promote cell proliferation and melanin synthesis | [ |
| Skin fibroblasts and keratinocytes | ROS and mitochondrial membrane potential | NaHS | Accelerate wound healing and improve blood flow | [ |
| Oral mucosa, peritoneal macrophages, and RAW264.7 cells | NF- | GYY4137 | Inhibit mucosal wound inflammation and accelerate wound healing | [ |
| Skin fibroblast cell lines (AG11395 and AG12795) | mTOR pathway | NaHS | Restore a normal morphologic phenotype | [ |
| Mouse skin and lung |
| NaHS | Alleviate the severity of systemic sclerosis-associated skin and lung fibrosis | [ |
| A375 human melanoma | NF- | DATS | Inhibit melanoma proliferation, invasion, and metastasis | [ |
| B16- F10 cells | AKT/ERK pathway | CSE substrate L-cysteine or DATS | Inhibit tumour growth | [ |
| A375 and SK-MEL-28 human melanoma | PI3K/AKT/mTOR pathway | NaHS | Inhibit tumour growth, migration, and cell cycle | [ |
| A375 and basal cell carcinoma cells | Cytosolic Ca2+, ROS, and mitochondrial membrane potential | DATS | Inhibit tumour growth | [ |
| A375 human melanoma | Integrin/FAK pathway | DATS | Inhibit cell migration and invasion | [ |
| A375 human melanoma | Caspase 3 | Naproxen-HBTA | Suppress human melanoma cell proliferation, migration, invasion, and colony formation | [ |